近年来,阴性杆菌感染特别是绿脓杆菌与大肠杆菌引起的感染发病率有所增加,治疗比较困难,失败率较高。抗阴性杆菌抗菌素虽然已有不少品种,但能有效控制绿脓杆菌与耐药大肠杆菌感染的抗菌素为数不多,而且存在不少问题,很难满足临床需要。多粘菌素类抗菌素对绿脓杆菌与大肠杆菌在体外均有较好杀菌作用,但因他们在体内对肾脏具有一定毒性,治疗剂量受到严格限制,对重症感染的疗效并不满意。庆大霉素是目前临床上广泛使用的氨基糖甙类抗菌素,体外试验绿脓杆菌对其敏感性较高,但临床疗 In recent years, negative bacilli infections, especially Pseudomonas aeruginosa and Escherichia coli caused an increase in the incidence of infection, the treatment is more difficult, a higher failure rate. Antibacterial antibacterial bacilli Although there are many varieties, but can effectively control Pseudomonas aeruginosa and drug-resistant Escherichia coli antibiotic few, but there are many problems, it is difficult to meet the clinical needs. Polymyxins antibiotics on Pseudomonas aeruginosa and Escherichia coli have good bactericidal effect in vitro, but because of their in vivo toxicity to the kidney, the treatment dose is severely restricted, the efficacy of severe infections are not satisfied. Gentamicin is currently widely used in clinical aminoglycoside antibiotics, Pseudomonas aeruginosa in vitro test its sensitivity, but clinical treatment